Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82


Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.

Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, Koenig KB, Lee MH, Hortobagyi GN, Yeung SC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):63-72. doi: 10.1007/s00280-012-1977-9. Epub 2012 Sep 28.


Leptin regulates cyclin D1 in luminal epithelial cells of mouse MMTV-Wnt-1 mammary tumors.

Zheng Q, Hursting SD, Reizes O.

J Cancer Res Clin Oncol. 2012 Sep;138(9):1607-12. doi: 10.1007/s00432-012-1252-9. Epub 2012 Jun 13.


Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.

Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.

Breast Cancer Res. 2012 Feb 21;14(1):R35.


Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR.

Biochim Biophys Acta. 2012 Apr;1825(2):207-22. doi: 10.1016/j.bbcan.2012.01.002. Epub 2012 Jan 24. Review.


Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.

Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Bonofiglio D, Bossi G, Covington KR, Fuqua SA, Andò S.

Cancer Res. 2012 Mar 15;72(6):1416-27. doi: 10.1158/0008-5472.CAN-11-2558. Epub 2012 Jan 26.


Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways.

Yan D, Avtanski D, Saxena NK, Sharma D.

J Biol Chem. 2012 Mar 9;287(11):8598-612. doi: 10.1074/jbc.M111.322800. Epub 2012 Jan 23.


Effects of energy restriction and wheel running on mammary carcinogenesis and host systemic factors in a rat model.

Zhu Z, Jiang W, Zacher JH, Neil ES, McGinley JN, Thompson HJ.

Cancer Prev Res (Phila). 2012 Mar;5(3):414-22. doi: 10.1158/1940-6207.CAPR-11-0454. Epub 2012 Jan 13.


Obesity and breast cancer: a clinical biochemistry perspective.

Ray A, Cleary MP.

Clin Biochem. 2012 Feb;45(3):189-97. doi: 10.1016/j.clinbiochem.2011.11.016. Epub 2011 Dec 8. Review.


Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E.

BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90.


Targeting the leptin receptor: a potential new mode of treatment for breast cancer.

Otvos L Jr, Surmacz E.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1147-50. doi: 10.1586/era.11.109. No abstract available.


Caloric restriction reduces growth of mammary tumors and metastases.

De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzúa P, Vatner SF, Rabson AB.

Carcinogenesis. 2011 Sep;32(9):1381-7. doi: 10.1093/carcin/bgr107. Epub 2011 Jun 10.


Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells.

Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D.

Endocr Relat Cancer. 2011 Jul 1;18(4):413-28. doi: 10.1530/ERC-11-0075. Print 2011 Aug.


Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.

Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E.

Eur J Cancer. 2011 Jul;47(10):1578-84. doi: 10.1016/j.ejca.2011.01.018. Epub 2011 Feb 23.


Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3.

Kim SH, Nagalingam A, Saxena NK, Singh SV, Sharma D.

Carcinogenesis. 2011 Mar;32(3):359-67. doi: 10.1093/carcin/bgq267. Epub 2010 Dec 16.


Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo.

Park J, Kusminski CM, Chua SC, Scherer PE.

Am J Pathol. 2010 Dec;177(6):3133-44. doi: 10.2353/ajpath.2010.100595. Epub 2010 Nov 5.


Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis.

Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK.

Hepatology. 2010 Nov;52(5):1713-22. doi: 10.1002/hep.23892.


Energy balance, host-related factors, and cancer progression.

Hursting SD, Berger NA.

J Clin Oncol. 2010 Sep 10;28(26):4058-65. doi: 10.1200/JCO.2010.27.9935. Epub 2010 Aug 9. Review.


Adiponectin and breast cancer.

Chen X, Wang Y.

Med Oncol. 2011 Dec;28(4):1288-95. doi: 10.1007/s12032-010-9617-x. Epub 2010 Jul 13. Review.


The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.

Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC.

J Cell Mol Med. 2011 Apr;15(4):825-36. doi: 10.1111/j.1582-4934.2010.01083.x.


Metformin: a therapeutic opportunity in breast cancer.

Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2010 Mar 15;16(6):1695-700. doi: 10.1158/1078-0432.CCR-09-1805. Epub 2010 Mar 9. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk